Mallinckrodt faces investor lawsuit for allegedly making false statements about its financial health

But 13 months later, the company is back in desperate straits. In regulatory filings, Mallinckrodt has admitted its failure to make its annual $200 million opioid settlement payment and suggested that bankruptcy again is in the offing.

And last week, its investors piled on, filing a class-action lawsuit against the company. In federal court in New Jersey, the investors accused Mallinckrodt of making false and misleading statements about the financial health of the company.